Optinose Set to Be Acquired by Paratek Pharmaceuticals for Up to $330 Million

Deal News | Mar 20, 2025 | EIN

Optinose Set to Be Acquired by Paratek Pharmaceuticals for Up to $330 Million

Optinose, Inc. experiences a significant stock surge following the announcement of a merger agreement with Paratek Pharmaceuticals. The agreement, approved by the boards of both companies, outlines that Paratek will acquire Optinose for up to $330 million, providing Optinose shareholders with a significant premium. The deal includes a cash offer of $9 per share and additional contingent value rights (CVRs) if Optinose's XHANCE achieves certain revenue targets. Paratek aims to leverage the acquisition to expand its portfolio, while Optinose sees it as a chance to broaden the impact of XHANCE. The transaction is expected to finalize by mid-2025, pending customary closing conditions and shareholder approval. Upon completion, Optinose will no longer be listed on the NASDAQ Global market. The announcement has drastically improved investor sentiment from bearish to bullish, as seen on investment platforms like Stocktwits.

Sectors

  • Pharmaceuticals
  • Mergers & Acquisitions

Geography

  • United States – The companies involved, Paratek Pharmaceuticals and Optinose, are based in the U.S. and the transaction pertains to the U.S. market.

Industry

  • Pharmaceuticals – The article discusses a merger involving pharmaceutical companies, Paratek Pharmaceuticals and Optinose, focusing on a drug-device product for chronic rhinosinusitis.
  • Mergers & Acquisitions – The article centers around a merger announcement and the strategic acquisition plan by Paratek Pharmaceuticals to acquire Optinose.

Financials

  • Up to $330 million – The total potential value of the acquisition agreement between Paratek Pharmaceuticals and Optinose.
  • $9 per share – The cash offer price per Optinose share as part of the merger agreement.
  • Up to $5 per share in CVRs – Contingent value rights offered per share if certain revenue benchmarks for XHANCE are achieved.

Participants

NameRoleTypeDescription
Optinose, Inc.Target CompanyCompanyA pharmaceutical company with a focus on products for the treatment of chronic rhinosinusitis, including their product XHANCE.
Paratek PharmaceuticalsBidding CompanyCompanyA privately held pharmaceutical company looking to acquire Optinose to expand its product portfolio.
Ramy MahmoudCEO of OptinosePeopleCEO of Optinose who commented on the benefits of the merger for XHANCE and shareholder value.